{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:22:31Z","timestamp":1776079351593,"version":"3.50.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T00:00:00Z","timestamp":1648857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Gilead Sciences, Inc. Gilead Sciences K.K. and Galapagos NV"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Characterize safety of the Janus kinase-1 preferential inhibitor filgotinib (FIL) in Japanese patients with moderately to severely active rheumatoid arthritis (RA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from three Phase 3 trials (NCT02889796, NCT02873936, and NCT02886728) and a long-term extension (NCT03025308) through September 2019 were integrated; patients received \u22651 dose of FIL 200 (FIL200) or 100\u2009mg (FIL100) daily, or placebo (PBO). We calculated exposure-adjusted incidence rates (EAIRs) per 100 patient-years FIL exposure (100PYE) for treatment-emergent adverse events (TEAEs) and adverse events of special interest.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 3691 total patients and 6080.7 PYE, 229 Japanese patients received FIL for 311.4 PYE (median 1.5, maximum 2.5\u2009years). During the 12-week PBO-controlled period, serious TEAEs and TEAEs leading to study drug disruption were comparable between FIL and PBO. Serious infection rates were 1.9%, 0%, and 2% for FIL200, FIL100, and PBO during the PBO-controlled period; long-term FIL200 and FIL100 EAIRs were 3.8 and 2.1\/100PYE. No herpes zoster (HZ) or major adverse cardiovascular events (MACEs) occurred during the PBO-controlled period; long-term FIL200 and FIL100 EAIRs were 3.0 and 2.1\/100PYE (HZ) and 0.6 and 0\/100PYE (MACE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Long-term FIL treatment (median 1.5, maximum 2.5\u2008years exposure) was well tolerated at 100- and 200-mg doses in Japanese patients with RA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roac020","type":"journal-article","created":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T02:01:41Z","timestamp":1648864901000},"page":"64-72","source":"Crossref","is-referenced-by-count":6,"title":["Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5\u2009years"],"prefix":"10.1093","volume":"33","author":[{"given":"Naoki","family":"Ishiguro","sequence":"first","affiliation":[{"name":"Aichi Development Disability Center , Kasugai, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health , Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Matsubara Mayflower Hospital , Kat\u014d, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University , Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Saitama Medical University , Kawagoe, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Hiroshima University , Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8858-9435","authenticated-orcid":false,"given":"Kunihiro","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine , Sagamihara, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Winthrop","sequence":"additional","affiliation":[{"name":"Department of Public Health and Preventive Medicine, Oregon Health and Science University , Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[{"name":"Altoona Center for Clinical Research , Duncansville, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd R","family":"Burmester","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 University Hospital Berlin , Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Strasbourg University Hospital , Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark C","family":"Genovese","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Matzkies","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deyuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrix","family":"Bartok","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alena","family":"Pechonkina","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kondo","sequence":"additional","affiliation":[{"name":"Gilead Sciences K.K. , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Besuyen","sequence":"additional","affiliation":[{"name":"Galapagos NV , Mechelen, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,4,2]]},"reference":[{"key":"2023011210571905300_R1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"2023011210571905300_R2","doi-asserted-by":"crossref","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res"},{"key":"2023011210571905300_R3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2023011210571905300_R4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","article-title":"Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis","volume":"29","author":"Kameda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2023011210571905300_R5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023011210571905300_R6","volume-title":"Japanese Package Insert","author":"Jyseleca\u00ae (Filgotinib Maleate Tablets)","year":"2020"},{"key":"2023011210571905300_R7","volume-title":"Summary of Product Characteristics","author":"Jyseleca\u00ae (Filgotinib) 100 mg Film-Coated Tablets","year":"2020"},{"key":"2023011210571905300_R8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/annrheumdis-2021-221051","article-title":"Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023011210571905300_R9","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3899\/jrheum.161196","article-title":"Association between medications and herpes zoster in Japanese patients with rheumatoid arthritis: a 5-year prospective cohort study","volume":"44","author":"Harada","year":"2017","journal-title":"J Rheumatol"},{"key":"2023011210571905300_R10","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023011210571905300_R11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023011210571905300_R12","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023011210571905300_R13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial","volume":"80","author":"Westhovens","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023011210571905300_R14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.semarthrit.2008.10.002","article-title":"The risk of infections with biologic therapies for rheumatoid arthritis","volume":"39","author":"Furst","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"2023011210571905300_R15","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2023011210571905300_R16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","article-title":"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment","volume":"52","author":"Listing","year":"2013","journal-title":"Rheumatology"},{"key":"2023011210571905300_R17","article-title":"Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Patients (DARWIN3)","volume-title":"Clinicaltrials.gov, US National Library of Medicine","author":"US National Library of Medicine","year":"2021"},{"key":"2023011210571905300_R18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40264-021-01067-x","article-title":"The safety profile of upadacitinib in patients with rheumatoid arthritis in Japan","volume":"44","author":"Yamaoka","year":"2021","journal-title":"Drug Saf"},{"key":"2023011210571905300_R19","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-0932-2","article-title":"Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study","volume":"18","author":"Yamanaka","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2023011210571905300_R20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40744-021-00280-5","article-title":"Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: final results (32 months of mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan","volume":"8","author":"Takeuchi","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2023011210571905300_R21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/14397595.2019.1583711","article-title":"Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of Phases 2 and 3 trials","volume":"30","author":"Harigai","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2023011210571905300_R22","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20936059","article-title":"JAK inhibitors and infections risk: focus on herpes zoster","volume":"12","author":"Sunzini","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2023011210571905300_R23","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-eular.1408","article-title":"Herpes zoster in the filgotinib rheumatoid arthritis program","volume":"80","author":"Winthrop","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac020\/43290386\/roac020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/1\/64\/48626575\/roac020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/1\/64\/48626575\/roac020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T12:17:26Z","timestamp":1673525846000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/1\/64\/6562537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,2]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,4,2]]},"published-print":{"date-parts":[[2023,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac020","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,4,2]]}}}